Wall Street Signals: Medifocus, Inc. Announces 26% Increase in Revenue in Recent Quarter and Positive Cash Flow from Operation for the Six Months Ended Sept 30, 2018

Medifocus, Inc. Announces 26% Increase in Revenue in Recent Quarter and Positive Cash Flow from Operation for the Six Months Ended Sept 30, 2018



Medifocus, Inc. (MDFZF) and (MFS.V) ("Medifocus" or the "Company"), a biotechnology company with a portfolio of medical products encompassing thermotherapy systems for the treatment of Benign Prostatic Hyperplasia (BPH) and Breast Cancer, reported a 26% increase in revenue for the quarter ending September 30, 2018, and a 14% increase for the six months ending September 30, 2018, compared to the same periods in 2017.

Prolieve® sales were $704,195 for the quarter ended September 30, 2018, compared to $557,600 for the same period in 2017. For the six months ended September 30, 2018, sales increased to $1,441,585 from $1,266,500 for the same period in 2017. Operating loss for the six months ended September 30,2018 was reduced by 53% to $185,740, compared to $383,199 for the same period in 2017. Not only did Medifocus achieve its first ever annual positive cash flow of $21,544 from operating activities for the fiscal year ended March 31, 2018, compared to using $1,937,326 cash in operating activities during the fiscal year ended March 31, 2016, the Company also recorded a $10,151 positive cash flow from operating activities for the six months ended September 30, 2018, compared to using $83,359 and $389,268 cash in operating activities during the six months ended September 30,2017 and September 30, 2016, respectively.

Dr. William Jow, President and Chief Executive Officer of Medifocus, remarked, "Since I progressed toward becoming CEO two years back, we have considerably decreased working misfortunes by enhancing operational viability. We are satisfied to see the uptick in income from Prolieve® activity in the last two quarters and to accomplish maintainability with positive income. While we will stay careful on cost investment funds and quality, we are ready to become our Prolieve® business by utilizing the positive clinical discoveries from our Post Approval Study (PAS) as of late finished and acknowledged by the U.S. FDA. The 12-year PAS with 5-year follow-up information affirm long haul security, adequacy and solidness of Prolieve® in treating men with BPH, bringing about enhanced lower urinary tract side effects, urinary stream rate, personal satisfaction, and with negligible or no sexual reactions when contrasted with an untreated age-coordinated male populace."

About the Prolieve® Thermodilatation™ System
The Prolieve® Thermodilatation™ System offers potential relief to the millions of men who suffer from Benign Prostatic Hyperplasia (BPH), a condition that becomes common as men age. About half of men over 50 have some enlargement of the prostate gland, and this rises to about 90% among those over 70. As the prostate enlarges, it constricts the urethra, thereby restricting the passage of urine. Persistent restriction and further progression of BPH, if left untreated, often results in worsening of lower urinary tract symptoms (LUTS). Further complications of this process may result in urinary retention, bladder stones and infection, as well as compromised bladder and kidney function.
The Prolieve® System is a novel focused heat therapy which utilizes a unique combination of focused heat energy directed at the prostate in combination with a patented, water cooled and pressurized dilatation balloon to achieve immediate and long-term relief of BPH symptoms with very minimal treatment-related side effects after a brief in-office procedure performed under local anesthesia. The unique advantage of this combined "heat plus compression" therapy is twofold: first, the heat denatures local tissue proteins of the (balloon) dilated urethra, resulting in an expanded and stiffened urethral lumen functioning as a biological stent. Second, the compression reduces local blood flow thus increasing the thermal efficiency of the microwave energy to achieve apoptosis and tissue ablation in the targeted prostate gland. As the transurethral microwave energy is applied to the entire prostate, a computerized feedback system involving the rectal temperature probe renders the rectal temperature not to exceed 41-42 C, thus ensuring the safety of the rectal wall and neurovascular bundles essential to the preservation of erectile function.